Stoke Therapeutics, Inc.

Listed Company

STOKCIK 0001623526NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$184.42M

Net Income

$-6.88M

Total Assets

$418.43M

Equity

$352.46M

Shares Out

59.15M

Op. Cash Flow

$45.59M

Business

Stoke Therapeutics, Inc. develops RNA-based medicines that upregulate protein expression using its proprietary TANGO platform to treat severe genetic diseases caused by haploinsufficiency. Its main products are antisense oligonucleotide (ASO) therapeutics, including lead candidates zorevunersen for Dravet syndrome and STK-002 for autosomal dominant optic atrophy, alongside discovery and preclinical programs targeting CNS and ocular disorders. The company operates development and commercialization activities, research collaborations and licensing partnerships, and outsources manufacturing to third-party contractors. It conducts global clinical trials and targets commercial availability via direct commercialization in North America and partnered distribution internationally.

Summary from filing dated 2025-03-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	184	37	9	12	—
Research and development	138	89	82	78	54
Sales, general and administrative	67	49	—	—	—
Total operating expenses	205	138	124	117	86
Loss from operations	−21	−101	−115	−104	−86
Interest income (expense), net	14	13	10	3	120,000
Other income (expense), net	−51,000	−247,000	166,000	167,000	140,000
Total other income (expense)	14	12	10	3	260,000
Net loss	−7	−89	−105	−101	−86
Net loss per share, basic	−0.12	−1.65	−2.38	−2.6	−2.34
Net loss per share, diluted	−0.12	−1.65	−2.38	−2.6	−2.34
Weighted-average common shares outstanding, basic	59	54	44	39	37
Weighted-average common shares outstanding, diluted	59	54	44	39	37
Unrealized gain (loss) on marketable securities	694,000	−127,000	1	−1	−168,000
Total other comprehensive gain (loss)	694,000	−127,000	1	−1	−168,000
Comprehensive loss	−6	−89	−104	−102	−86

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-07-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	84	—	128	191	114
Marketable securities - short term	200	—	89	10	116
Accounts receivable	6	—	2	—	—
Prepaid expenses	9	—	11	11	11
Other current assets	4	—	2	3	3
Restricted cash - short term	494,000	—	75,000	—	—
Interest receivable	2	—	700,000	64,000	588,000
Total current assets	306	—	233	215	244
Restricted cash - long term	227,000	—	721,000	569,000	569,000
Operating lease right-of-use assets	3	2	4	7	5
Marketable securities - long term	106	—	30	—	—
Property and equipment, net	3	—	4	6	7
Total assets	418	—	272	228	256
Accounts payable	5	—	2	2	766,000
Accrued and other current liabilities	41	—	19	14	16
Deferred revenue - current portion	12	—	19	15	15
Total current liabilities	58	—	40	31	31
Deferred revenue - net of current portion	7	—	—	33	37
Other long term liabilities	1	—	2	5	3
Total long term liabilities	8	—	2	38	40
Total liabilities	66	—	43	69	71
Commitments and contingencies (Note 7)	—	—	—	—	—
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 58,921,999 and 54,032,826 shares issued and outstanding as of December 31, 2025 and 2024, respectively	5,000	—	5,000	5,000	4,000
Additional paid-in capital	850	—	720	561	483
Accumulated other comprehensive income (loss)	543,000	—	−151,000	−24,000	−1
Accumulated deficit	−498	—	−491	−402	−297
Total stockholders equity	352	—	229	160	185
Total liabilities and stockholders equity	418	—	272	228	256

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−7	−89	−105	−101	−86
Depreciation	2	2	3	2	1
Amortization and accretion of marketable securities	−1	−2	−325,000	−211,000	143,000
Stock-based compensation	32	27	25	23	16
Impairment of right of use asset	696,000	—	—	—	—
Loss on disposal of property and equipment	145,000	—	1,000	—	29,000
Reduction in the carrying amount of right of use assets	2	2	2	2	1
Accounts receivable	−4	−50,000	—	—	—
Prepaid expenses and other current assets	−545,000	−2	529,000	−5	−3
Accounts payable, accrued liabilities, and operating leases	21	3	−3	−4	—
Deferred revenue	−130,000	−29	−3	52	—
Net cash provided by (used in) operating activities	46	−87	−81	−32	−67
Purchases of property and equipment	−670,000	−203,000	−2	−4	−1
Purchases of marketable securities	−323	−167	0	−201	−87
Sales of marketable securities	137	60	108	159	12
Net cash used in investing activities	−187	−107	106	−46	−76
Proceeds from issuance of common stock upon exercise of stock options	9	2	371,000	494,000	777,000
Proceeds from employee stock purchase plan	1	532,000	555,000	570,000	509,000
Proceeds from controlled equity offering sales agreement, net of commissions	88	9	52	—	—
Proceeds from follow-on offering, net of underwriting discounts, commissions and offering costs	—	120	—	—	—
Net cash provided by financing activities	97	131	53	46	1
Net decrease in cash, cash equivalents and restricted cash	−44	−63	78	−31	−142
Right-of-use assets recognized in exchange for operating leases	2	—	4	2	5
Property and equipment included in accrued expense and accounts payable	482,000	61,000	0	121,000	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro